The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Expansion Is Expected For The T Cell Specific Surface Glycoprotein CD28 Market Over The Forecast Period?
The t cell specific surface glycoprotein cd28 market size has seen substantial growth in recent years. It is anticipated to increase from $1.62 billion in 2025 to $1.78 billion in 2026, at a compound annual growth rate (CAGR) of 10.0%. The expansion observed in the past can be attributed to the early recognition of cd28 as a t-cell co-stimulatory receptor, a rise in immunology research, the increasing occurrence of autoimmune diseases, growing initiatives in cancer research, and the constrained access to monoclonal antibody therapies.
The t cell specific surface glycoprotein cd28 market size is anticipated to experience robust growth over the next few years. It is forecast to reach $2.58 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.7%. The expansion during the projected period can be attributed to the development of lulizumab pegol and innovative cd28 inhibitors, the increasing number of preclinical and clinical trials, the integration of cd28-targeted treatments into autoimmune and cancer therapies, rising investments in biopharmaceutical research, and advancements in immunomodulation and monoclonal antibody engineering. Key trends for the forecast period include the growing adoption of flow cytometry and ELISA technologies, an increase in immunology and cancer research applications, the progressing development of novel cd28 inhibitors and biobetters, the expansion of stem cell and autoimmune disease research, and the incorporation of lulizumab pegol in preclinical and clinical studies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp
Which Strategic Drivers Are Supporting The T Cell Specific Surface Glycoprotein CD28 Market Development?
The increasing focus on personalized medicine is anticipated to fuel the expansion of the T cell-specific surface glycoprotein CD28 market moving forward. Personalized medicine is a medical approach that tailors treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for this approach is rising due to advancements in genomic technologies, which facilitate the precise identification of genetic variations and customized treatments for individuals. T cell-specific surface glycoprotein CD28 supports personalized medicine by enabling targeted immune modulation, making therapies more precise and effective. It enhances treatment outcomes by promoting optimal T cell activation, thereby improving patient-specific immune responses. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, an increase from 12 approved in 2022. Thus, the growing emphasis on personalized medicine is driving the growth of the T cell-specific surface glycoprotein CD28 market.
How Is The T Cell Specific Surface Glycoprotein CD28 Market Structured Across Different Market Segments?
The t cell specific surface glycoprotein cd28 market covered in this report is segmented –
1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types
2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry
3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers
4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research
5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories
Subsegments:
1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships
2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations
3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering
4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds
What Trends Are Impacting The T Cell Specific Surface Glycoprotein CD28 Market?
Key players within the T cell-specific surface glycoprotein CD28 market are prioritizing the creation of innovative offerings, particularly combination immunotherapies, aimed at elevating T cell activation, enhancing anti-tumor efficacy, and improving patient outcomes. Such immunotherapies involve therapeutic strategies that merge several immune-centric methods to strengthen the body’s natural defense against illness. An illustrative example occurred in February 2025, when Rondo Therapeutics Inc., a biopharmaceutical firm based in the US, unveiled preclinical findings concerning RNDO 564, an innovative CD28 Nectin 4 costimulatory bispecific antibody designed for advanced bladder cancer. This antibody is engineered to specifically activate CD28 on T cells when it binds to tumor cells that express Nectin-4, thereby boosting T-cell-mediated tumor elimination while concurrently reducing toxicity to healthy cells. The gathered data exhibited strong anti-tumor activity in preclinical models, lending support for its continued development as a prospective treatment for individuals suffering from metastatic urothelial carcinoma.
Which Companies Are Engaged In The T Cell Specific Surface Glycoprotein CD28 Market Environment?
Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.
Access The Complete T Cell Specific Surface Glycoprotein CD28 Market Report:
Which Regional Market Leads The T Cell Specific Surface Glycoprotein CD28 Market?
North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access T Cell Specific Surface Glycoprotein CD28 Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp
Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2026, By The Business Research Company
Monitor Market Report 2026
https://www.thebusinessresearchcompany.com/report/monitor-global-market-report
Display Monitor Market Report 2026
https://www.thebusinessresearchcompany.com/report/display-monitor-global-market-report
Holter Monitor Market Report 2026
https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model